RA after 70: Too Old for bioDMARDs?

Save

In RA, the two most common peaks of incidence are thirties and fifties; however a significant percentage of patients above the age of 70 present with active RA -of early or later onset- and require adapted treatment.

EULAR 2021 - Day 2 Podcasts

Save

Check out this compilation of our EULAR 2021 Day 2 broadcasts below.

You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com

Listen by Clicking below:

RheumNow Podcast - EULAR 2021 & EULAR-IQ (6.4.21)

Save

Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.

EULAR Best Abstracts - Day 2

Save

The second day of EULAR 2021 took a big leap in online content.  #EULAR2021 generated 2500 tweets yesterday. Here is a compilation (with links) of presentations were the “Best” as seen by our RheumNow faculty. 

New GRAPPA 2021 PsO and PsA Treatment Recommendations

Save

The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021.

Is Rituximab and Belimumab the Combination to Beat Lupus?

Save

On day 2 of EULAR conference, Dr. Michael Ehrenstein presented OP0129, a presentation on the BEAT-LUPUS trial looking at belimumab therapy after rituximab. B cell depletion with rituximab is common treatment for refractory SLE, though real-world data for rituximab has been uncertain. It is known that B-cell activating factor (BAFF) levels can increase after rituximab, which can lead to disease flares. Using belimumab, a human monoclonal antibody inhibiting BAFF, could be a potential therapeutic option after rituximab infusions. 

EULAR 2021 – Day 2 Report

Save

During Day 2 there were great sessions devoted to RA, spondylarthritis, fatigue and more.  Here are some of my highlights from Day 2.

New insights in RA-ILD therapeutics

Save

RA associated ILD (RA-ILD) is the most common extra-articular manifestation in RA. Its prevalence varies considerably, ranging from 5% to 30%, and is often underestimated since patients only become symptomatic or display abnormalities on chest X-Ray at a late stage of disease, leading to subsequent delay in diagnosis. In this context, several groups advocate for an earlier and more precise detection, using high resolution chest computed tomography (HRCT), which is the most sensitive for pre-clinical RA-ILD diagnosis. But why would we want to diagnose early a manifestation that we cannot treat?

Turning the Corner on CV Risk in Rheumatoid Arthritis

Save

Cardiovascular (CV) disease remains the leading cause of mortality in rheumatoid arthritis (RA). A number of studies progressed our knowledge in the session Rheumatoid arthritis - comorbidity and clinical aspects – I on Thursday at EULAR 2021.

EULAR 2021 – Day 1 Report

Save

After the opening ceremonies and keynote speaker there were several enticing sessions and a plenary session full of great research and presentations.  Here are a few of the highlights that I saw.

EULAR 2021 - Day 1 Podcasts

Save

Check out this compilation of our EULAR 2021 Day 1 broadcasts below.

You can follow the EULAR 2021 RheumNow podcasts on iTunes and Soundclound.com

Listen by Clicking below:

Day 1a

EULAR 2021 - Opening Day

Save

RheumNow has begun covering EULAR 2021, the premier Rheumatology Congress that is usually held in Europe, but has gone virtual in 2021 because of the pandemic. We have several faculty members around the world reporting on the this year's meeting. Please visit RheumNow.com daily for the latest videos, tweet summaries, news articles and podcasts emanating from EULAR. Look for our coverage on these and other important topics: